India, Oct. 6 -- Lupin to remain in focus after the company announced the launch of Formoflo-G MDI on October 6, 2026. The product has been approved by the Drug Controller General of India (DCGI) for the long-term treatment and management of moderate to severe chronic obstructive pulmonary disease (COPD).

Shares of Lupin Limitedwere trading at Rs. 2,015 per share on October 6, 2026, up by 0.20 percent from the previous close of Rs. 2,011 apiece. With a market capitalization of around Rs. 92,043 crore, the stock is trading at a P/E of 15.4.

Strengthening Respiratory Franchise The launch comes as Lupin continues to build its presence in respiratory therapies. The company ranked #2 in India's respiratory therapy segment as of MAT March 20...